Q3 EPS Estimate for Arcturus Therapeutics Lifted by Analyst

Key Points

• The Q3 2025 earnings per share (EPS) estimate for Arcturus Therapeutics has been raised from ($0.81) to ($0.58) by William Blair analysts.
• Arcturus Therapeutics reported Q2 earnings of ($0.34) EPS, surpassing expectations of ($1.11) EPS with a revenue of $28.30 million.
• The stock price of Arcturus Therapeutics has seen a significant increase of 29.0% recently, currently trading around $19.21.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at William Blair upped their Q3 2025 earnings per share (EPS) estimates for shares of Arcturus Therapeutics in a report released on Tuesday, August 12th. William Blair analyst M. Minter now expects that the biotechnology company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.81). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics' Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.15) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at $1.83 EPS.

ARCT has been the subject of several other research reports. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Citigroup reaffirmed a "buy" rating and set a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a report on Tuesday. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.00.

Arcturus Therapeutics Stock Up 29.0%

NASDAQ:ARCT opened at $19.21 on Thursday. The company has a market cap of $521.74 million, a P/E ratio of -8.61 and a beta of 2.26. Arcturus Therapeutics has a twelve month low of $8.04 and a twelve month high of $25.88. The business has a 50 day moving average price of $13.29 and a two-hundred day moving average price of $13.30.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. The firm had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Arcturus Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock worth $9,421,000 after purchasing an additional 3,186 shares during the period. Wells Fargo & Company MN increased its position in shares of Arcturus Therapeutics by 12.6% in the fourth quarter. Wells Fargo & Company MN now owns 69,664 shares of the biotechnology company's stock worth $1,182,000 after purchasing an additional 7,785 shares during the period. Kennedy Capital Management LLC increased its position in shares of Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 2,036 shares during the period. MetLife Investment Management LLC increased its position in shares of Arcturus Therapeutics by 21.5% in the fourth quarter. MetLife Investment Management LLC now owns 16,676 shares of the biotechnology company's stock worth $283,000 after purchasing an additional 2,955 shares during the period. Finally, Hsbc Holdings PLC increased its position in shares of Arcturus Therapeutics by 11.8% in the fourth quarter. Hsbc Holdings PLC now owns 25,368 shares of the biotechnology company's stock worth $424,000 after purchasing an additional 2,673 shares during the period. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.